IL2 and type 1 diabetes mellitus: The limited efficacy of Treg-based immunotherapy in T1D may depend on the limited number of residual functional beta-cells at time of treatment, the inadequate availability of IL-2 in vivo (40), or, more importantly, on the lack of antigen-specificity of the infused Tregs.